FIELD: biotechnology.
SUBSTANCE: invention relates to production of immunocytokines with interleukin-2, and can be used in medicine for treating cancer. Presented is an anti-tumor fusion protein containing a whole anti-PDL1 antibody as a therapeutic protein coupled with a mutant interleukin-2 (IL2) polypeptide. Mutant IL2 polypeptide is linked to the C-ends of each heavy chain of the antibody by a serine-glycine linker sequence.
EFFECT: invention provides obtaining immunocytokine with high anticancer potential, capable of selectively inducing preferential proliferation of CD8+T-cells and NK-cells relative to T-reg cells.
7 cl, 13 dwg, 11 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
